Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Metabolism and disposition of lesinurad, a uric acid reabsorption inhibitor, in humans.

Shah V, Yang C, Shen Z, Kerr BM, Tieu K, Wilson DM, Hall J, Gillen M, Lee CA.

Xenobiotica. 2019 Jul;49(7):811-822. doi: 10.1080/00498254.2018.1504257. Epub 2018 Sep 12.

PMID:
30117757
2.

Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine.

Xiang AX, Webber SE, Kerr BM, Rueden EJ, Lennox JR, Haley GJ, Wang T, Ng JS, Herbert MR, Clark DL, Banh VN, Li W, Fletcher SP, Steffy KR, Bartkowski DM, Kirkovsky LI, Bauman LA, Averett DR.

Nucleosides Nucleotides Nucleic Acids. 2007;26(6-7):635-40.

PMID:
18066870
3.

RNA loading of leukemic antigens into cord blood-derived dendritic cells for immunotherapy.

Hsu AK, Kerr BM, Jones KL, Lock RB, Hart DN, Rice AM.

Biol Blood Marrow Transplant. 2006 Aug;12(8):855-67.

4.

Pharmacokinetic interaction of nelfinavir and methadone in intravenous drug users.

Hsyu PH, Lillibridge J, Daniels E, Kerr BM.

Biopharm Drug Dispos. 2006 Mar;27(2):61-8.

PMID:
16299829
5.

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection.

Horsmans Y, Berg T, Desager JP, Mueller T, Schott E, Fletcher SP, Steffy KR, Bauman LA, Kerr BM, Averett DR.

Hepatology. 2005 Sep;42(3):724-31.

PMID:
16116638
6.

Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine.

O'Rourke MG, Johnson M, Lanagan C, See J, Yang J, Bell JR, Slater GJ, Kerr BM, Crowe B, Purdie DM, Elliott SL, Ellem KA, Schmidt CW.

Cancer Immunol Immunother. 2003 Jun;52(6):387-95. Epub 2003 Apr 8.

PMID:
12682787
7.

Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir.

Tran JQ, Petersen C, Garrett M, Hee B, Kerr BM.

Clin Pharmacol Ther. 2002 Dec;72(6):615-26.

PMID:
12496743
8.

Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers.

Hsyu PH, Pithavala YK, Gersten M, Penning CA, Kerr BM.

Antimicrob Agents Chemother. 2002 Feb;46(2):392-7.

9.

Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.

Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM.

Antimicrob Agents Chemother. 2001 Dec;45(12):3445-50.

10.

Delavirdine: clinical pharmacokinetics and drug interactions.

Tran JQ, Gerber JG, Kerr BM.

Clin Pharmacokinet. 2001;40(3):207-26. Review.

PMID:
11327199
11.

A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial.

Jackson KA, Rosenbaum SE, Kerr BM, Pithavala YK, Yuen G, Dudley MN.

Antimicrob Agents Chemother. 2000 Jul;44(7):1832-7.

12.

Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate.

Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty BV, Lee CA.

Drug Metab Dispos. 1998 Jul;26(7):609-16.

PMID:
9660842
13.

Pharmacokinetics and metabolism of the novel anticonvulsant agent N-(2,6-dimethylphenyl)-5-methyl-3-isoxazolecarboxamide (D2624) in rats and humans.

Martin SW, Bishop FE, Kerr BM, Moor M, Moore M, Sheffels P, Rashed M, Slatter JG, Berthon-C├ędille L, Lepage F, Descombe JJ, Picard M, Baillie TA, Levy RH.

Drug Metab Dispos. 1997 Jan;25(1):40-6.

PMID:
9010628
14.

Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus.

Kerr BM, Kienzle N, Burrows JM, Cross S, Silins SL, Buck M, Benson EM, Coupar B, Moss DJ, Sculley TB.

J Virol. 1996 Dec;70(12):8858-64.

15.

Pharmacokinetics of bismuth and ranitidine following multiple doses of ranitidine bismuth citrate.

Koch KM, Kerr BM, Gooding AE, Davis IM.

Br J Clin Pharmacol. 1996 Aug;42(2):207-11.

16.

Recruitment during infectious mononucleosis of CD3+CD4+CD8+ virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1.

White CA, Cross SM, Kurilla MG, Kerr BM, Schmidt C, Misko IS, Khanna R, Moss DJ.

Virology. 1996 May 15;219(2):489-92.

17.

Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918.

Witherspoon SM, Emerson DL, Kerr BM, Lloyd TL, Dalton WS, Wissel PS.

Clin Cancer Res. 1996 Jan;2(1):7-12.

18.

Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans.

Dixon CM, Colthup PV, Serabjit-Singh CJ, Kerr BM, Boehlert CC, Park GR, Tarbit MH.

Drug Metab Dispos. 1995 Nov;23(11):1225-30.

PMID:
8591723
19.

Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation.

Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH.

Biochem Pharmacol. 1994 Jun 1;47(11):1969-79.

PMID:
8010982
20.

Protection from phenytoin-induced congenital malformations by coadministration of the antiepileptic drug stiripentol in a mouse model.

Finnell RH, Kerr BM, van Waes M, Steward RL, Levy RH.

Epilepsia. 1994 Jan-Feb;35(1):141-8.

PMID:
8112237
21.

Differences in the patterns of phenytoin-induced malformations following stiripentol coadministration in three inbred mouse strains.

Finnell RH, van Waes M, Musselman A, Kerr BM, Levy RH.

Reprod Toxicol. 1993 Sep-Oct;7(5):439-48.

PMID:
8274819
22.

Stiripentol in atypical absence seizures in children: an open trial.

Farwell JR, Anderson GD, Kerr BM, Tor JA, Levy RH.

Epilepsia. 1993 Mar-Apr;34(2):305-11.

PMID:
8453942
23.

Measurement of in vivo microsomal epoxide hydrolase activity in white subjects.

Kroetz DL, Kerr BM, McFarland LV, Loiseau P, Wilensky AJ, Levy RH.

Clin Pharmacol Ther. 1993 Mar;53(3):306-15.

PMID:
8453849
24.

Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis.

Finnell RH, Buehler BA, Kerr BM, Ager PL, Levy RH.

Neurology. 1992 Apr;42(4 Suppl 5):25-31.

PMID:
1574173
25.

Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage.

Kerr BM, Lear AL, Rowe M, Croom-Carter D, Young LS, Rookes SM, Gallimore PH, Rickinson AB.

Virology. 1992 Mar;187(1):189-201.

PMID:
1310556
26.

Exclusion of the familial melanoma locus (MLM) from the PND/D1S47 and MYCL1 regions of chromosome arm 1p in 7 Australian pedigrees.

Nancarrow DJ, Palmer JM, Walters MK, Kerr BM, Hafner GJ, Garske L, McLeod GR, Hayward NK.

Genomics. 1992 Jan;12(1):18-25.

PMID:
1531137
27.

Pharmacokinetic consequences of product stereoselectivity in the metabolism of nafimidone: estimation of fraction metabolized.

Kerr BM, Boddy AV, Moreland TA, Levy RH.

J Pharm Sci. 1991 Aug;80(8):812-4. No abstract available.

PMID:
1791547
28.

Carbamazepine dose requirements during stiripentol therapy: influence of cytochrome P-450 inhibition by stiripentol.

Kerr BM, Martinez-Lage JM, Viteri C, Tor J, Eddy AC, Levy RH.

Epilepsia. 1991 Mar-Apr;32(2):267-74.

PMID:
2004631
29.

Unsubstituted amides: new class of potent inhibitors of human microsomal epoxide hydrolase.

Kerr BM, Levy RH.

Drug Metab Dispos. 1990 Jul-Aug;18(4):540-2. No abstract available.

PMID:
1976080
30.

Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation.

Kerr BM, Rettie AE, Eddy AC, Loiseau P, Guyot M, Wilensky AJ, Levy RH.

Clin Pharmacol Ther. 1989 Jul;46(1):82-93. Erratum in: Clin Pharmacol Ther 1989 Sep;46(3):343.

PMID:
2501059
31.

Inhibition of epoxide hydrolase by anticonvulsants and risk of teratogenicity.

Kerr BM, Levy RH.

Lancet. 1989 Mar 18;1(8638):610-1. No abstract available.

PMID:
2564126
32.

Pharmacokinetics of old, new, and yet-to-be-discovered antiepileptic drugs.

Levy RH, Kerr BM.

Epilepsia. 1989;30 Suppl 1:S35-41; discussion S64-8.

PMID:
2776710
33.

Clinical pharmacokinetics of carbamazepine.

Levy RH, Kerr BM.

J Clin Psychiatry. 1988 Apr;49 Suppl:58-62. Review.

PMID:
3280563
34.

Supplemental Content

Support Center